Stephen L. Rawlings

Array ( [id] => 11704633 [patent_doc_number] => 20170173131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS' [patent_app_type] => utility [patent_app_number] => 15/374480 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 43723 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15374480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11820636 [patent_doc_number] => 20170209573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'TREATMENT METHOD' [patent_app_type] => utility [patent_app_number] => 15/371891 [patent_app_country] => US [patent_app_date] => 2016-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 76670 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15371891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706263 [patent_doc_number] => 20170174762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'BIPARATOPIC POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS' [patent_app_type] => utility [patent_app_number] => 15/367323 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 27945 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15367323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514324 [patent_doc_number] => 20170081398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/367955 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 41903 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15367955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13968331 [patent_doc_number] => 10213499 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers [patent_app_type] => utility [patent_app_number] => 16/065681 [patent_app_country] => US [patent_app_date] => 2016-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 21 [patent_no_of_words] => 40668 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026481 [patent_doc_number] => 10035856 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells [patent_app_type] => utility [patent_app_number] => 15/355511 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 17818 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 333 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866206 [patent_doc_number] => 20170233490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'HER3/HER2 BISPECIFIC ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 AND DOMAIN II OF HER2' [patent_app_type] => utility [patent_app_number] => 15/348588 [patent_app_country] => US [patent_app_date] => 2016-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 44528 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15348588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618370 [patent_doc_number] => 20170128557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'Dendritic Cell Therapeutic Agent and Immunotherapeutic Agent Comprising Peptide Derived from Telomerase, and Therapeutic Methods Using the Same' [patent_app_type] => utility [patent_app_number] => 15/346870 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9943 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15346870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11500697 [patent_doc_number] => 20170074882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'METHOD FOR COLORECTAL CANCER DETECTION' [patent_app_type] => utility [patent_app_number] => 15/342378 [patent_app_country] => US [patent_app_date] => 2016-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 1571 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15342378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15245261 [patent_doc_number] => 10508143 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-12-17 [patent_title] => Compositions and methods for treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/315844 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 95 [patent_figures_cnt] => 139 [patent_no_of_words] => 48477 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15315844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864786 [patent_doc_number] => 20170232070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'Combination Methods for Immunotherapy' [patent_app_type] => utility [patent_app_number] => 15/333127 [patent_app_country] => US [patent_app_date] => 2016-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 27236 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15333127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11455963 [patent_doc_number] => 20170049870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'Antigen Peptide Derived From the Sequence of Epidermal Growth Factor Receptor Having T790M Point Mutation' [patent_app_type] => utility [patent_app_number] => 15/299775 [patent_app_country] => US [patent_app_date] => 2016-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 6825 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15299775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12139492 [patent_doc_number] => 20180017575 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'HISTONE PROTEIN UBIQUITINATION AS A CANCER BIOMARKER' [patent_app_type] => utility [patent_app_number] => 15/286693 [patent_app_country] => US [patent_app_date] => 2016-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14030 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15286693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604072 [patent_doc_number] => 11332543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => Antibody polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 15/761260 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14915 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15761260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395211 [patent_doc_number] => 20170015747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/281441 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 35414 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15281441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729341 [patent_doc_number] => 20170190783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/281484 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 56330 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15281484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11589734 [patent_doc_number] => 20170114146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'Bispecific T cell activating antigen binding molecules' [patent_app_type] => utility [patent_app_number] => 15/282994 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 49292 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15282994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542661 [patent_doc_number] => 20170096485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/279799 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 51489 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15279799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542670 [patent_doc_number] => 20170096495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/279738 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 50109 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15279738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15540879 [patent_doc_number] => 10570205 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Human antigen binding proteins that bind b-Klotho, FGF receptors and complexes thereof [patent_app_type] => utility [patent_app_number] => 15/280662 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 88 [patent_no_of_words] => 54200 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15280662 [rel_patent_id] =>[rel_patent_doc_number] =>)